

091-25508 for

For Internal Use Only		Submit 1 Original		OMB Approval No.:
Sec File No. 91 -		and 9 Copies		Expires:

Estimated average burden hours per response: 2.00

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION  
Washington, D.C. 20549  
FORM 19b-4(e)**

**Information Required of a Self-Regulatory Organization Listing and Trading a New  
Derivative Securities Product Pursuant to Rule 19b-4(e) Under the Securities Exchange Act of 1934**

**READ ALL INSTRUCTIONS PRIOR TO COMPLETING FORM**

**Part I Initial Listing Report**

1. Name of Self-Regulatory Organization Listing New Derivative Securities Product:

**NYSE Arca, Inc. (trading pursuant to unlisted trading privileges)**

2. Type of Issuer of New Derivative Securities Product (e.g., clearinghouse, broker-dealer, corporation, etc.):

**Open-end Management Investment Company**

3. Class of New Derivative Securities Product:

**Investment Company Units**

4. Name of Underlying Instrument:

**Loncar China BioPharma Index**

5. If Underlying Instrument is an Index, State Whether it is Broad-Based or Narrow-Based:

**Narrow-Based**

6. Ticker Symbol(s) of New Derivative Securities Product:

**CHNA**

7. Market or Markets Upon Which Securities Comprising Underlying Instrument Trades:

**Hong Kong, Nasdaq, NYSE**

8. Settlement Methodology of New Derivative Securities Product:

**Regular way trades settle on T+2/Book entry only held in DTC.**

9. Position Limits of New Derivative Securities Product (if applicable):

**Not applicable.**

**Part II Execution**

The undersigned represents that the governing body of the above-referenced Self-Regulatory Organization has duly approved, or has duly delegated its approval to the undersigned for, the listing and trading of the above-referenced new derivative securities product according to its relevant trading rules, procedures, surveillance programs and listing standards.

Name of Official Responsible for Form:

**Martha Redding**

Title:

**Associate General Counsel and Assistant Secretary**

Telephone Number:

**(212) 656-2938**

Manual Signature of Official Responsible for Form:

*[Signature]*

**August 17, 2018**

SEC 2449 (1/99)

SEC Mail Processing  
AUG 20 2018  
Washington, DC



18010320

Securities and Exchange Commission  
Trading and Markets

AUG 21 7 01 AM '18

Act	Securities Exchange Act of 1934
Section	19b-4
Rule	19b-4(e)
Public Availability:	<b>AUG 20 2018</b>

**RECEIVED**



Martha Redding  
Associate General Counsel  
Assistant Secretary

New York Stock Exchange  
11 Wall Street  
New York, NY 10005  
T + 1 212 656 2938  
F + 1 212 656 8101  
Martha.Redding@theice.com

**Via Overnight Mail**

August 17, 2018

Ms. Claudette Ransom  
US Securities and Exchange Commission  
Division of Trading and Markets  
Station Place – Building I  
100 F Street, N.E. – Room 7010  
Washington, DC 20549

SEC Mail Processing

AUG 20 2018

Washington, DC

**Re: 19b-4(e) – Transmittal (NYSE Arca, Inc.)**

Dear Ms. Ransom:

Enclosed for filing pursuant to Section 19(b) of the Securities Exchange Act of 1934 and Rule 19b-4 thereunder, please find an original and nine copies of Form 19b-4(e) with respect to the securities listed below.

**Loncor China BioPharma ETF (CHNA)**

If you have any questions, please do not hesitate to call me at (212) 656-2938.

Sincerely,

Securities and Exchange Commission  
Trading and Markets

AUG 21 2018

RECEIVED

Enclosures